This site is intended for Healthcare Professionals only.

Biocon secures approval for its drug to be used on Covid-19 patients

Date:

Share post:

India’s Biocon Ltd has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical company said in a statement on Saturday (July 11).

The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in India.

“The randomised control trial indicated that all the patients treated with Itolizumab responded positively and recovered,” said Kiran Mazumdar-Shaw, the firm’s executive chairperson.

The control group which did not receive Itolizumab unfortunately suffered deaths, she said, adding that the “first-in-class” drug will save lives and help reduce the mortality rate in India.

Clinical studies involving the drug are being closely watched as nations look for treatments for the disease that has infected over 820,000 people and killed over 22,000 in india.

India recorded 27,114 coronavirus cases in the last 24 hours. The South Asian country’s coronavirus case tally has made it the nation with the third-biggest outbreak, behind only the United States and Brazil in confirmed infections.

The DGCI earlier this month approved pharmaceutical firm Zydus Cadila to start phase one and phase two human clinical trials of its Covid-19 vaccine. Itolizumab is the second vaccine to gain approval after Hyderabad-based Bharat Biotech’s COVAXIN.

 (Reuters)

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

How Bioprocess Containers Improve Vaccine Transportation

Have you ever wanted to know how vaccines are sent out from a lab to your doctor’s office...

Celebrating the Festival of Lights: Diwali messages from pharmacy leaders

As the country celebrates Diwali, symbolising the victory of good over evil and of light over darkness, Pharmacy...

Autumn Budget 2024: Pharmacies ‘deeply worried’ about National Insurance rise

No mention of action to halt pharmacy closure in the Autumn Budget upsets community pharmacies The new Labour...

Autumn Budget 2024: What it has for retail businesses?

The new Labour government’s first Budget reduces business rates and allocates £1.9 billion to support small businesses and...